Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.21 USD | -3.07% | -12.34% | -4.57% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 740M |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -166M | EV / Sales 2024 * | - |
Net Debt 2024 * | 952K | Net Debt 2025 * | 13.89M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.89
x | P/E ratio 2025 * |
-4.93
x | Employees | 72 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.35% |
Latest transcript on ALX Oncology Holdings Inc.
1 day | -3.07% | ||
1 week | -12.34% | ||
Current month | -16.51% | ||
1 month | -9.72% | ||
3 months | -10.35% | ||
6 months | +49.58% | ||
Current year | -4.57% |
Managers | Title | Age | Since |
---|---|---|---|
Jaume Pons
FOU | Founder | 58 | 15-03-31 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Peter García
DFI | Director of Finance/CFO | 62 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 22-11-27 |
Corey Goodman
CHM | Chairman | 72 | 15-02-28 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +11.05% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 14.21 | -3.07% | 199,968 |
24-05-16 | 14.66 | -2.40% | 224,310 |
24-05-15 | 15.02 | -0.99% | 321,855 |
24-05-14 | 15.17 | -2.82% | 385,283 |
24-05-13 | 15.61 | -3.70% | 438,228 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.57% | 740M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ALXO Stock